Follicular lymphoma treatments are improving; however, there are subgroups of patients who still have poor outcomes. Here, Marek Trneny, MD, PhD, of Charles University, Prague, Czech Republic, evaluates different prognostic indices and their utility in follicular lymphoma management, at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. He touches upon existing indices like FLIPI and FLIPI2, before focusing on the prognostic index developed from the PRIMA study (NCT00140582). The PRIMA-PI uses ?2-microglobulin level to categorize patients into risk level groups. Dr Trneny discusses how, after testing this index with his own group of patients, it was found to be more simple and robust than other prognostic indices, establishing it as a useful tool for directing treatment in the clinical setting.